brilliant blue G ophthalmic (Rx)

Brand and Other Names:TissueBlue
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, intravitreal solution

  • 0.025% solution in prefilled 2.25-mL syringe (filled to volume of 0.5 mL)

Internal Limiting Membrane Staining

Disclosing agent indicated to selectively stain the internal limiting membrane

Inject into balanced salt solution (BSS)-filled vitreous cavity using a blunt cannula attached to the prefilled syringe, without allowing the cannula to contact the retina or allowing stain to get under the retina

Sufficient staining is expected within a few seconds

Remove all excess dye from vitreous cavity following staining

Safety and efficacy not established

Next:

Adverse Effects

Frequency Not Defined

Adverse reactions reported in procedures that included use of brilliant blue G ophthalmic solution have often been associated with the surgical procedure; complications include retinal break, tear, hemorrhage, and detachment and cataracts

Previous
Next:

Warnings

Contraindications

None

Cautions

Excessive staining; remove excess solution from eye immediately after staining

Ensure the syringe plunger moves smoothly before injecting the solution; do not use if plunger does not move smoothly to prime cannula

Previous
Next:

Pregnancy & Lactation

Pregnancy

Data are not available on the use in pregnant women to inform a drug-associated risk

Systemic absorption in humans is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures

Owing to negligible systemic exposure, it is not expected that maternal use will result in fetal exposure to the drug

Adequate animal reproduction studies were not conducted

Lactation

Data are not available; however, breastfeeding is not expected to result in drug exposure of the child

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Brilliant Blue G has been shown to selectively stain the internal limiting membrane, but not the epiretinal membrane or the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated

Previous
Next:

Administration

Intravitreal Administration

Inject into balanced salt solution (BSS)-filled vitreous cavity using a blunt cannula attached to the prefilled syringe, without allowing the cannula to contact the retina or allowing stain to get under the retina

Sufficient staining is expected within a few seconds

Remove all excess dye from vitreous cavity following staining

Storage

Store at 15-25ºC (59-77ºF)

Protect from light, frost, and moisture

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.